Simile raises $200M Series B at $2B valuation, just 5 months after Series A
Original: Synthetic-user startup Simile raises $200M at $2B valuation 5 months after $100M Series A
Why This Matters
Simile's rapid fundraising trajectory highlights surging VC investment in AI-driven synthetic user research tools.
Synthetic-user startup Simile closed a $200M Series B at a $2B valuation on July 30, 2026, only five months after its $100M Series A led by Index Ventures. The round was led by Greenoaks with participation from Bain Capital Ventures, CVS Health Ventures, and others.
Simile, a startup offering AI-simulated users for marketing and product research, has raised a $200 million Series B at a $2 billion valuation. The round was led by Greenoaks, with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures. CVS Health Ventures is also listed as a marquee customer of the company.
The funding comes just five months after Simile emerged from stealth with a $100 million Series A led by Index Ventures. The company was founded by Stanford PhD graduate Joon Sung Park, whose dissertation included a project called "Smallville," in which AI agents simulated human lives, including social activities like parties.
Simile's stated mission is to simulate "all eight billion people on earth, accurately and honestly." The startup operates in a growing segment of AI-powered synthetic user research, alongside competitors such as Aaru, which raised a Series A in December 2025 at a $1 billion valuation.